OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Rutkowski on JPB898 With Ipilimumab in Stage III or Metastatic Stage IV Melanoma

July 22nd 2025

Piotr Rutkowski, MD, discusses a trial evaluating the nivolumab biosimilar JPB898 plus ipilimumab in stage III or metastatic stage IV melanoma.

Dr Komrokji on the Clinical Integration of Imetelstat for Lower-Risk MDSLR-MDS

July 22nd 2025

Rami Komrokji, MD, shares advice on how to integrate imetelstat into clinical practice for transfusion-dependent lower-risk myelodysplastic syndromes.

Dr Pan on Late-Onset Toxicities Associated With CAR T-Cell Therapy in Multiple Myeloma

July 22nd 2025

Darren Pan, MD, outlines late-onset toxicities related to CAR T-cell therapies in multiple myeloma and their management.

Dr Markman on Future Research Directions in Gynecologic Oncology

July 21st 2025

Maurie Markman, MD, discusses future research considerations in gynecologic oncology.

Dr Scarfò on the Future of BGB-16673 in Relapsed/Refractory CLL/SLL

July 21st 2025

Lydia Scarfò, MD, discusses future research directions for BGB-16673 in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Dr Gill on Considering Patients’ Concerns Before Treatment Selection in Advanced CRC

July 21st 2025

Sharlene Gill, MD, MPH, MBA, FRCPC, highlights the importance of considering patients’ concerns ahead of treatment decision-making for advanced CRC.

Dr Hammers on the Efficacy of IO/TKI and IO/IO Regimens in ccRCC

July 18th 2025

Hans Hammers, MD, PhD, discusses the main efficacy differences between IO/TKI and IO/IO combinations in clear-cell renal cell carcinoma.

Dr Rugo on the Safety Profile of Alpelisib in PI3K-Mutant HR+/HER2– Advanced Breast Cancer

July 18th 2025

Hope S. Rugo, MD, discusses the safety profile of alpelisib for the treatment of PI3K-mutant HR-positive/HER2-negative advanced breast cancer.

Dr Maese on the Use of Pediatric-Inspired Regimens in AYA and Adult ALL

July 18th 2025

Luke Maese, DO, discusses how the evolution of AYA and adult ALL management may be inspired by treatment protocols used in the pediatric population.

Dr Kotecha on the Potential of ENPP3 as a Therapeutic Target in ccRCC

July 18th 2025

Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.

Dr Sfakianos on Outcomes With Intravesical Mitomycin for Recurrent, Low-Grade, Intermediate-Risk NMIBC

July 18th 2025

John Sfakianos, MD, shared findings from an analysis of mitomycin intravesical solution from the phase 3 ENVISION trial in recurrent NMIBC.

Dr Sabari on Efficacy of Zidesamtinib in TKI-Pretreated, Advanced, ROS1+ NSCLC

July 18th 2025

Joshua K. Sabari, MD, discusses response rates observed with zidesamtinib in patients with advanced ROS1-positive non–small cell lung cancer.

Dr Runcie on Treatment Approaches in RCC After Progression on Adjuvant Therapy

July 18th 2025

Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.

Dr Powles on Results from a Q-TWiST Analysis of Belzutifan vs Everolimus in Previously Treated Advanced RCC

July 17th 2025

Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.

Dr Machaalani on the Potential Role of Circulating KIM-1 as a Biomarker in Metastatic RCC

July 17th 2025

Marc Machaalani, MD, discusses retrospective findings from a multi-platform analysis evaluating circulating KIM-1 as a biomarker in metastatic RCC.

Dr Duska on PFS2 Data With Pembrolizumab and Chemoradiotherapy in Cervical Cancer

July 17th 2025

Linda R. Duska, MD, MPH, discusses PFS2 data with pembrolizumab plus chemoradiotherapy in newly diagnosed, high-risk cervical cancer.

Dr Finn on Tiragolumab Plus Atezolizumab and Bevacizumab in HCC

July 17th 2025

Richard S. Finn, MD, discusses the background of the MORPHEUS-Liver trial of tiragolumab plus atezolizumab and bevacizumab in HCC.

Dr Hamilton on Unmet Needs for Brain Metastases in HER2+ Metastatic Breast Cancer

July 17th 2025

Erika P. Hamilton, MD, highlights the unmet needs regarding treatment for brain metastases in HER2-positive metastatic breast cancer.

Dr Eng on Real-World Outcomes in US Patients With KRAS G12C–Mutated CRC

July 16th 2025

Cathy Eng, MD, FACP, FASCO, discusses a real-world study of the effect of KRAS G12C mutations on outcomes in patients with metastatic colorectal cancer.

Dr Thaker on IMNN-001 Plus Neoadjuvant Chemo in Newly Diagnosed Ovarian Cancer

July 16th 2025

Premal H. Thaker, MD, MS, discusses data from a study of IMN-001 plus neoadjuvant chemotherapy in newly diagnosed epithelial ovarian cancer.